1394 Preclinical characterization of biodegradable injectable antigen presenting nanoparticles AIM I...
1394 Preclinical characterization of biodegradable injectable antigen presenting nanoparticles AIM INJ for in vivo treatment of solid tumors
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundNexImmune’s artificial immune modulation (AIM™) technology is designed to direct T cell function and drive a T cell-mediated response. AIM antigen-specific immunotherapies rely on a nanoparticle-based artificial antigen presenting cell (aAPC) platform. The off-the-shelf injectable nanoparticles (INJ) are developed using biodegradable PLGA...
Alternative Titles
Full title
1394 Preclinical characterization of biodegradable injectable antigen presenting nanoparticles AIM INJ for in vivo treatment of solid tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2840781748
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2840781748
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2022-SITC2022.1394
